Granite Point Capital Management, L.P. Clovis Oncology, Inc. Transaction History

Granite Point Capital Management, L.P.

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2018 Aug 13, 2018	SELL	$42.06 - $62.4 $555,192 - $823,680	-13,200 Closed	0 $0
Q1 2018 May 15, 2018	SELL	$50.12 - $67.72 $340,816 - $460,496	-6,800 Reduced 34.0%	13,200 $697,000
Q4 2017 Feb 08, 2018	SELL	$57.69 - $84.58 $617,283 - $905,006	-10,700 Reduced 34.85%	20,000 $1.36 Million
Q3 2017 Nov 14, 2017	SELL	$67.17 - $84.81 $624,681 - $788,733	-9,300 Reduced 23.25%	30,700 $2.53 Million
Q2 2017 Aug 10, 2017	BUY	N/A	40,000	40,000 $3.75 Million

166

Ticker CLVS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 144,480,000
Market Cap $13M
Description
Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. In the U.S., the company offers Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase for recurrent epithelial ovarian, fallopian tube, or pr...

Get notified when there are updates to the investment portfolio of Granite Point Capital Management, L.P., based on Form 13F filings with the SEC.

Stay updated on Granite Point Capital Management, L.P. with notifications on news.